A detailed history of Alliancebernstein L.P. transactions in Uni Qure N.V. stock. As of the latest transaction made, Alliancebernstein L.P. holds 178,600 shares of QURE stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
178,600
Holding current value
$1.03 Million
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $675,108 - $1.81 Million
178,600 New
178,600 $880,000
Q3 2023

Nov 14, 2023

SELL
$6.71 - $11.83 $628,498 - $1.11 Million
-93,666 Reduced 48.14%
100,916 $677,000
Q2 2023

Aug 15, 2023

SELL
$11.12 - $22.2 $3.14 Million - $6.27 Million
-282,539 Reduced 59.22%
194,582 $2.23 Million
Q1 2023

May 15, 2023

SELL
$18.7 - $23.07 $578,540 - $713,739
-30,938 Reduced 6.09%
477,121 $9.61 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $3.29 Million - $4.97 Million
181,791 Added 55.72%
508,059 $11.5 Million
Q3 2022

Nov 15, 2022

SELL
$16.98 - $25.54 $3.04 Million - $4.57 Million
-178,888 Reduced 35.41%
326,268 $6.12 Million
Q2 2022

Aug 15, 2022

BUY
$13.15 - $20.45 $2.34 Million - $3.63 Million
177,745 Added 54.29%
505,156 $9.42 Million
Q1 2022

May 13, 2022

BUY
$14.54 - $21.5 $2.76 Million - $4.08 Million
189,980 Added 138.24%
327,411 $5.92 Million
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $1.2 Million - $2.14 Million
59,472 Added 76.29%
137,431 $2.85 Million
Q3 2021

Nov 10, 2021

BUY
$26.01 - $38.22 $1.2 Million - $1.76 Million
46,036 Added 144.21%
77,959 $2.5 Million
Q2 2021

Jul 30, 2021

BUY
$29.97 - $37.17 $956,732 - $1.19 Million
31,923 New
31,923 $983,000
Q1 2021

May 06, 2021

SELL
$29.24 - $42.03 $874,802 - $1.26 Million
-29,918 Closed
0 $0
Q4 2020

Feb 08, 2021

BUY
$35.35 - $50.67 $1.06 Million - $1.52 Million
29,918 New
29,918 $1.08 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.